Clonal Architecture of ASXL1-mutated Myelofibrosis

Recruiting now · Not applicable

Conditions studied: Myelofibrosis

In brief

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Key facts

Study ID

NCT05710211

Run by

University Hospital, Angers

People needed

50

Starts

2023-04-24

Expected to finish

2031-04-23

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (age ≥18 years),
• Affiliated to the national social security system,
• ASXL1 mutated primary or secondary myelofibrosis,
• Signed the consent to participate in the study,
• Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).

You may not qualify if…

• Patient with another active hematological disease or cancer at the time of diagnosis,
• Person subject to legal protection scheme or incapable of giving consent.

Where it is running

• Hôpital Bicêtre — Paris, France (enrolling)
• CHU de Bordeaux — Pessac, France (enrolling)
• CHU Lyon — Pierre-Bénite, France (enrolling)
• CHU Henri MONDOR — Créteil, France (enrolling)
• CHRU Tours - Hôpital Bretonneau — Tours, France (enrolling)
• CHU Angers — Angers, France (enrolling)
• Institut Paoli Calmettes — Marseille, France (enrolling)
• CH de Vannes — Vannes, France
• CHRU Brest — Brest, France
• CH Cholet — Cholet, France
• CHU Nantes — Nantes, France
• AP-HP Hôpital Saint Louis — Paris, France
• CH de Cornouaille — Quimper, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.